The Drug Science Podcast

Professor Glue hopes that his development of oral ketamine (rather than intravenous) will bring ketamine treatment from the clinics “back to people’s bathrooms”.

Show Notes

This week’s episode features Paul Glue, professor of Psychiatry at the Dunedin School of Medicine, University of Otago, New Zealand.

With a vast experience in both academia and pharmaceutical industry, Paul Glue's research focuses on clinical and basic science to investigate the pharmacology of drug treatments in psychiatry and the disease mechanisms of neurological and psychiatric disorders. He is also interested in psychopharmacology and the development of novel therapeutics for affective disorders. One of these novel substances that have dominated his career is ketamine for treatment-resistant depression. 

Tune in to this episode to listen to a fascinating conversation between two great scientists about, well… Drug Science.

Ketamine

Ibogaine

National Institute on Alcohol Abuse and Alcoholism

Microdialysis

Electroconvulsive therapy (ECT)

NMDA glutamate receptor

Overexcitement and disinhibition
 Dynamic Neurotransmitter Interactions in Alcohol Withdrawal by Paul Glue and David Nutt 

Methamphetamine 

John Krystal

Treatment-resistant depression

Ketamine Assisted Psychotherapy

Montgomery-Asberg Depression Rating Scale

Douglas Pharmaceuticals

Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression

Mechanisms of ketamine action as an antidepressant - P Zanos, T D Gould

Food and Drug Administration (FDA)

Medicines and Healthcare products Regulatory Agency

Good manufacturing practice (GMP)

Paroxetine 

QT interval 

The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation

Noribogaine

Prozac

Psychedelics Promote Structural and Functional Neural Plasticity - Ly et al.

Serotonin 2a receptor

★ Support this podcast ★

What is The Drug Science Podcast?

Professor David Nutt has spent a career making the argument for a rational, evidence-based approach to drug policy and drug use. The scientific evidence still challenges perceived wisdom on drugs and for that reason can appear to be contentious. In this podcast, the Professor explores the actual harms and potential benefits of various drugs, challenging myths surrounding classification and legislation, and exploring the societal impact of poorly informed drug policy. Using evidence in public policy should not be controversial. A podcast for anyone interested in understanding the scientific truth about drugs, free from political or moral concern.